商品编号


YIF-LF-PA0190



品牌


Adipogen



公司


Adipogen



公司分类


Antibodies



Size

100 ?l

商品信息


More Information



Product Details



Synonyms

UB+1; Frameshift



Product Type

Polyclonal Antibody



Properties



Immunogen/Antigen

Synthetic peptide.



Application

Western Blot (1:5,000)
Immunoprecipitation (5 μl)



Crossreactivity

Human



Purity Detail

Protein A purified.



Concentration

1 mg/ml



Formulation

Liquid. HEPES with 0.15M NaCl, 0.01% BSA, 0.03% sodium azide, and 50% glycerol.



Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.



Declaration

Manufactured by AbFrontier



Shipping and Handling



Shipping

BLUE ICE



Short Term Storage

+4°C



Long Term Storage

-20°C



Use/St
ABI
lity

Stable for at least 1 year after receipt when stored at -20°C.



Documents



MSD
S

No



Product Specification Sheet



Datasheet


Download PDF





Ubiquitin+1 (Ub+1) is a novel mutant form of ubiquitin that can be produced through a process known as molecular frame shift. Ub+1 can be polyubiquitinated to produce aberrant polyubiquitin chains that inhibit the 26S proteasome. Especially ub+1 is accumulated in aggregates containing amyloid-β and phosphorylated-tau. Elevated expression of Ub+1 mRNA and protein has been observed in the brains of patients with Alzheimer's disease. Also Ub+1 acts as an aggravating factor in polyglutamine-induced neurodegeneration. Protein modifier which can be covalently attached to target lysines either as a monomer or as a lysine-linked polymer. Attachment to proteins as a Lys-48-linked polymer usually leads to their degradation by proteasome. Attachment to proteins as a monomer or as an alternatively linked polymer does not lead to proteasomal degradation and may be required for numerous functions, including maintenance of chromatin structure, regulation of gene expression, stress response, ribosome biogenesis and DNA repair.


Product References
1) Van Leeuwen, F.W. et al. (1998) Science, 279, 242-247. (General)
2) Van Leeuwen, F.W. et al. (1998) Trends Neurosci. 21(8), 331-335. (General)